Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × NSCLC × tipifarnib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Leukemia 4 Blast Crisis 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Leukemia, Myelomonocytic, Acute 3 Leukemia, Monocytic, Acute 3 Leukemia, Megakaryoblastic, Acute 3 Leukemia, Erythroblastic, Acute 3 Congenital Abnormalities 3 Pancreatic Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Carcinoma, Non-Small-Cell Lung 2 Anemia, Refractory, with Excess of Blasts 2 Vulvar Neoplasms 1 Vipoma 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Thrombocythemia, Essential 1 Testicular Neoplasms 1

Interventions

aflutinib 3 osimertinib 2 Radiotherapy 2 tipifarnib 1 apatinib 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡